Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
06-11 | Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA. | CI |
05-28 | Mithra Delays AGM Amid Monetization Process | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4.415 AUD | -4.85% | -3.29% | 255M | ||
0.216 EUR | -1.82% | -.--% | 15.99M | ||
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-82.78% | 15.99M | |
+1.92% | 95.18B | |
-0.13% | 37.55B | |
-10.43% | 33.75B | |
+77.76% | 28.2B | |
-14.82% | 15.63B | |
-3.06% | 13.63B | |
-12.76% | 11.5B | |
+181.73% | 10.81B | |
-53.92% | 9.23B |
- Stock Market
- Equities
- MITRA Stock
- News Mithra Pharmaceuticals S.A.
- Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring